Strategies to improve neurodevelopmental outcomes in babies at risk of neonatal hypoglycaemia. (July 2021)

• Record Type: Journal Article
• Authors: Alsweiler, Jane M; Harris, Deborah L; Harding, Jane E; McKinlay, Christopher J D
• Is Part Of: Lancet. Volume 5:Number 7(2021)
• Page Start: 513
• Page End: 523
• Publication Date: 2021-07
• Subjects: Pediatrics -- Periodicals; Children -- Health and hygiene -- Periodicals; Adolescent medicine -- Periodicals; Teenagers -- Health and hygiene -- Periodicals; 618.920005
• DOI: 10.1016/S2352-4642(20)30387-4
• Languages: English
• ISSNs: 2352-4642

Abstract

Summary: Neonatal hypoglycaemia is associated with adverse development, particularly visual-motor and executive function impairment, in childhood. As neonatal hypoglycaemia is common and frequently asymptomatic in at-risk babies—ie, those born preterm, small or large for gestational age, or to mothers with diabetes, it is recommended that these babies are screened for hypoglycaemia in the first 1–2 days after birth with frequent blood glucose measurements. Neonatal hypoglycaemia can be prevented and treated with buccal dextrose gel, and it is also common to treat babies with hypoglycaemia with infant formula and intravenous dextrose. However, it is uncertain if screening, prophylaxis, or treatment improves long-term outcomes of babies at risk of neonatal hypoglycaemia. This narrative review assesses the latest evidence for screening, prophylaxis, and treatment of neonates at risk of hypoglycaemia to improve long-term neurodevelopmental outcomes.